ReviewBlood2011
The renaissance of interferon therapy for the treatment of myeloid malignancies.
Review in Blood, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03003325 (The Benefit/Risk Profile of Pegylated Proline-Interferon Alpha-2b), which is not on this map. Cited by 79 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Benefit/Risk Profile of Pegylated Proline-Interferon Alpha-2b (AOP2014) Added to the Best Available Strategy Based on Phlebotomies in Low-risk Patients With Polycythemia Vera (PV). The Low-PV Randomized Trial
Who cites it
79 citing papers in PubMed, 3 syntheses or guidelines pooled it, 206 citations in OpenAlex.
- Efficacy and safety of ropeginterferon in myeloproliferative neoplasms: a systematic review and meta-analysis.Frontiers in pharmacology · 2026Pooled it
- Interferon alpha therapy in essential thrombocythemia and polycythemia vera-a systematic review and meta-analysis.Leukemia · 2021Pooled it
- Interferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis.Clinical lymphoma, myeloma & leukemia · 2020Pooled it
- Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes.Annals of hematology · 2024Trial
- Trial
- Ruxolitinib versus standard therapy for the treatment of polycythemia vera.The New England journal of medicine · 2015Trial
- Trial
- A paradigm shift in the treatment of patients with polycythemia vera. The initial early use of recombinant interferon-alpha.Leukemia · 2026Review
- Modern and multidisciplinary care in polycythemia vera.Annals of hematology · 2026Review
- The Dual Role of Interferon Signaling in Myeloproliferative Neoplasms: Pathogenesis and Targeted Therapeutics.Cancers · 2025Review
- Clinical and Molecular Insights of Arterial and Venous Thrombosis in Myeloproliferative Diseases-Case-Based Narrative Review.Biomedicines · 2025Review
- Molecular characterization underlying IFN-α2 treatment in polycythemia vera: a transcriptomic overview.Molecular and cellular biochemistry · 2025Article
- Article
- Successful treatment of hairy cell leukaemia with pegylated interferon-alpha-2A.Pathology oncology research : POR · 2025Article
- Management of common autoimmune diseases in patients with myeloproliferative neoplasms treated with pegylated interferon alfa-case report, review of the literature and multidisciplinary clinical practice recommendations.Therapeutic advances in hematology · 2025Article
- Immune-dysregulation harnessing in myeloid neoplasms.Cancer medicine · 2024Review
- Interleukin-1β, JAK2V617F mutation and inflammation in MPNs.Blood advances · 2024Article
- Distinct clinico-molecular arterial and venous thrombosis scores for myeloproliferative neoplasms risk stratification.Leukemia · 2024Article
- Interferons in the treatment of myeloproliferative neoplasms.Therapeutic advances in hematology · 2024Review
- Toe Gangrene as the First Presenting Symptom of Essential Thrombocythemia: A Case Report.Cureus · 2023Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
IFNα has been used to treat malignant and viral disorders for more than 25 years. Its efficacy is likely the consequence of its broad range of biologic activities, including direct effects on malignant cells, enhancement of anti-tumor immune responses, induction of proapoptotic genes, inhibition of angiogenesis, and promotion of the cycling of dormant malignant stem cells. Because of the recent development of "targeted" therapies, the use of IFN has been dramatically reduced over the last decade. The increasing awareness of the multistep pathogenesis of many malignancies has suggested, however, that such an approach using target-specific agents is not universally effective. These observations have resulted in a number of recent clinical trials utilizing IFNα in patients with chronic myeloid leukemia (CML), systemic mast cell disease, hypereosinophilic syndrome and the Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) with promising outcomes. These reports provide evidence that IFNα, alone or in combination with other agents, can induce surprisingly robust molecular response rates and possibly improve survival. Although IFNα at present remains an experimental form of therapy for patients with myeloid malignancies, these promising results suggest that it may become again an important component of the therapeutic arsenal for this group of hematologic malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.